Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

HC, Gerstein; N, Sattar; J, Rosenstock; C, Ramasundarahettige; R, Pratley; RD, Lopes; CSP, Lam; NS, Khurmi; L, Heenan; Prato S, Del; L, Dyal; K, Branch

doi:10.1056/nejmoa2108269

Public

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Shared by NobleBlocks on Jun 28, 2021 • 12:00 AM UTC

Authors:

Gerstein HC

Sattar N

Rosenstock J

Abstract

<h4>Background</h4>Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on card...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!